AstraZeneca plcAstraZeneca has discontinued a pivotal Phase III trial of its dual checkpoint inhibitor volrustomig in metastatic non-small cell lung cancer (NSCLC), after an independent committee concluded that the study was unlikely to meet its primary endpoints. The setback comes as the company faces growing pressure to deliver new oncology products.
Tag Archive for: checkpoint
Flagging of CAR-T cells with the B7H6 protein weakened the response to human leukaemia in models as it marks them for NK cell attack, German researchers report.